Erratum: Erratum: Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension&#8482; Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study.

Sethi, Sanjay; Fogarty, Charles; Hanania, Nicola A; Martinez, Fernando J; Rennard, Stephen; Fries, Michael; Orevillo, Chad; Darken, Patrick; St Rose, Earl; Strom, Shannon; Fischer, Tracy; Golden, Michael; Dwivedi, Sarvajna; Reisner, Colin

Erratum: Erratum: Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study.

Sethi, Sanjay; Fogarty, Charles; Hanania, Nicola A; Martinez, Fernando J; Rennard, Stephen; Fries, Michael; Orevillo, Chad; Darken, Patrick; St Rose, Earl; Strom, Shannon; Fischer, Tracy; Golden, Michael; Dwivedi, Sarvajna; Reisner, Colin.

Afiliación

Sethi S; Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo.
Fogarty C; Spartanburg Medical Research, Spartanburg, South Carolina.
Hanania NA; Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas.
Martinez FJ; Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, New York.
Rennard S; Clinical Discovery Unit, AstraZeneca, Cambridge, Cambridgeshire, United Kingdom.
Fries M; Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, New York.
Orevillo C; Clinical Development, Pearl Therapeutics Inc., Morristown, New Jersey.
Darken P; Biostatistics, Pearl Therapeutics Inc., Morristown, New Jersey.
St Rose E; Clinical Operations, Pearl Therapeutics Inc., Morristown, New Jersey.
Strom S; Regulatory Affairs, Pearl Therapeutics Inc., Durham, North Carolina.
Fischer T; Regulatory Affairs, Pearl Therapeutics Inc., Durham, North Carolina.
Golden M; Regulatory Affairs, Pearl Therapeutics Inc., Durham, North Carolina.
Dwivedi S; Pearl Therapeutics Inc., Redwood City, California.
Reisner C; Clinical Development, Pearl Therapeutics Inc., Morristown, New Jersey.

Chronic Obstr Pulm Dis ; 4(3): 258, 2017 Apr 15.

Article en En | MEDLINE | ID: mdl-28853450

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Chronic Obstr Pulm Dis Año: 2017 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Chronic Obstr Pulm Dis Año: 2017 Tipo del documento: Article